Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Health Policy (Amsterdam, Netherlands)|February 20, 2008
A preliminary study into the economic burden of cerebral palsy in ChinaBin Wang, Yingyao Chen, Jie Zhang, et al.
Clinical Therapeutics|July 22, 2025
Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic EvaluationFuming Li, Dunming Xiao, Yu Xia, et al.
Frontiers in Public Health|April 12, 2021
A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice ExperimentFei Liu, Haiyao Hu, Jing Wang, et al.
International Journal of Integrated Care|March 27, 2020
Building a People-Centred Integrated Care Model in Urban China: A Qualitative Study of the Health Reform in LuohuDi Liang, Lin Mei, Yingyao Chen, et al.
Cost Effectiveness and Resource Allocation : C/E|July 28, 2023
Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancerHui Sun, Huishan Wang, Yan Wei, et al.
Patient Preference and Adherence|February 14, 2022
Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in ChinaLiu Liu, Yan Wei, Yue Teng, et al.
Cost Effectiveness and Resource Allocation : C/E|May 23, 2023
Assessment of equity and efficiency of magnetic resonance imaging services in Henan Province, ChinaXiaoling Huang, Yan Wei, Hui Sun, et al.
International Journal of Technology Assessment in Health Care|October 29, 2019
Mapping of Health Technology Assessment in China: Situation Analysis and International ComparisonYingyao Chen, Xunyouzhi Chi, Yao He, et al.
European Journal of Radiology|January 17, 2026
Economic evaluation of bulk packaging and single-dose packaging of contrast media for contrast-enhanced CTJie Jia, Yuxin Peng, Zhixu Zhu, et al.
Plos One|February 6, 2025
Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in ChinaDunming Xiao, Junling Weng, Lei Zhang, et al.
Pageof 13